** U.S.-listed shares of Israel based drug developer PainReform PRFX.O fall 18.4% to $4 premarket
** Co says its lead experimental pain relief treatment, PRF-110, did not meet the main goal of a late-stage study
** Co announced interim data from the late-stage study in November where it was testing PRF-110 to study the effect of the treatment in reducing pain over 72 hours
** Co had previously said that data from the late-stage pertaining to the last 24-hour period of the 72-hour study was unclear
** After further investigation co says the data could not be clarified to satisfy the study's main goal
** Co says despite setback, it has started R&D activities to better understand the effects of the treatment "to potentially resolve this issue to support future clinical trials"
** PRF-110 was tested to provide prolonged pain relief while reducing the need for opioids, in the post-surgical setting
** Up to last close, stock down 92.6% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。